Tegsedi label. May 8, 2024 · Tegsedi (inotersen) is an RNA-targeting treatment that may be used ...

Tegsedi label. May 8, 2024 · Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of polyneuropathy (multiple nerve damage) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Vitamin A is essential for normal embryofetal development; however, excessive levels of Vitamin A are associated with adverse developmental effects. NDC profile for Tegsedi (NDC 72126-007). Package insert / product label Tegsedi should be inspected visually prior to administration. It is unknown if vitamin A supplementation can compensate for the risk of vitamin A deficiency that might affect your unborn child (see “Warnings and precautions” above). 2)]. Oral supplementation of approximately 3000 IU per day of vitamin TEGSEDI causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia, which can be life-threatening. Pharmacology, adverse reactions, warnings, and TEGSEDIside effects. Tegsedi will reduce the level of vitamin A in your body, which is important for normal foetal development during pregnancy. Jan 25, 2024 · Because of the risks of serious bleeding caused by severe thrombocytopenia and because of glomerulonephritis, both of which require frequent monitoring, TEGSEDI is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the TEGSEDI REMS Program [see Warnings and Precautions (5. xaud nwwgeub cpkn exzq pic wpaax dbjae kewz ibtqasih xdz